Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ;Kombination aus AT1-blocker und hydrochlorothiazid zur blutdrucksenkung bei kardialen risikopatienten. Eine anwendungsbeobachtung mit Candesartan/HCT

MMW-Fortschritte der Medizin

Volumn 149, Issue SPEC. ISS. 4, 2008, Pages 172-181

  Bramlage, Peter ^a   Schönrock, Eleonore ^b   Odoj, Peter ^c   Wolf, Wolf Peter ^d   Funken, Christiane ^d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Praxis Schönrock   (Germany)

^c Praxis Odoj ^*  (Germany)

^d Takeda Pharma GmbH   (Germany)

Author keywords

24h blood pressure; Blood pressure reduction; Candesartan; Point of care research; Response; Tolerability

Indexed keywords

CANDESARTAN; CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MAJOR CLINICAL STUDY; MALE; PULSE PRESSURE; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; POSTMARKETING SURVEILLANCE; TREATMENT OUTCOME;

AGED; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 38749151602     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Asmar, R.: Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus. J. Renin Angiotensin Aldosterone Syst. 2 (Suppl. 2) (2001), S8-11.
2. Asmar, R., Vol, S., Brisac, A. M., Tichet, J., Topouchian, J.: Reference values for clinic pulse pressure in a nonselected population. Am. J. Hypertens. 14 (2001), 415-418.
3. Azizi, M., Nisse-Durgeat, S., French Collaborative Group: Comparison of the antihypertensive effects of the candesartan 8 mg hydrochlorothiazide 12.5 mg combination vs. the Valsartan 80 mg hydrochlorothiazide 12.5 mg combination in patients with essential hypertension resistant to monotherapy [abstract no. P2.367]. J. Hypertens. 22 (2004), S254-S255.
4. Baumgart, P., Reismann, J., Pohlmeyer, H., Düsing, R.: Wechsel von ACE-Hemmer, Ca-Antagonist oder beta-Blocker zu Candesartancilexetil: Bessere Wirksamkeit und Verträglichkeit. SWITCH-Studie (deutscher Studienteil). Dtsch. Med. Wochenschr. 126 (2001), 547-550.
5. Bonner, G., Fuchs, W.: Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr. Med. Res. Opin. 20 (2004), 597-602.
6. Bramlage, P., Bramlage, C., Kirch, W.: Pharmakoepidemiologie antihypertensiver Medikamente bei adipösen Patienten. Med. Klin. (München) 100 (2005), 804-809.
7. Chobanian, A. V., Bakris, G. L., Black, H. R., et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The INC 7 Report. J. Am. Med. Assoc. 289 (2003), 2560-2571.
8. Conroy, R. M., Pyorala, K., Fitzgerald, A. P., et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24 (2003), 987-1003.
9. Deutsche Hochdruckliga. Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie. Nieren-und Hochdruckkrankheiten 34 (2005), 481-498.
10. Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., He, J.: Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217-223.
11. Kearney, P. M., Whelton, M., Reynolds, K., Whelton, P. K., He, J.: Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 22 (2004), 11-19.
12. Klemsdal, T. O., Moan, A., Kjeldsen, S. E.: Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press. 8 (1999), 214-219.
13. Law, M. R., Wald, N. J., Morris, J. K., Jordan, R. E.: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br. Med. J. 326 (2003), 1427-1431.
14. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903-1913.
15. Mahmud, A., Feely, J.: Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J. Hum. Hypertens. 14 (2000), 541-546.
16. Mancia, G., De Backer, G., Dominiczak, A., et al.: Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25 (2007), 1105-1187.
17. Nink, K., Schröder, H.: Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe, U., Paffrath, D. (Hrsg.): Arzneimittelreport 2003. Berlin, Springer 2004, S. 959-971.
18. Philipp, T., Letzel, H., Arens, H. J.: Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J. Hum. Hypertens. 11 (Suppl. 2) (1997), S67-68.
19. Scholze, J.: Pulsdruck im therapeutischen Management der Hypertonie? Herz 29 (2004), 276-289.
20. Schulte, K. L., Fischer, M., Meyer-Sabellek, W.: Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs: results of the AURA study. Clin. Drug Inv. 18 (1999), 453-460.
21. Sever, P., Michel, J., Voet, B.: Candesartan cilexetil (CC): A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 11 (1998), 79A.
22. Sharma, A. M., Wittchen, H. U., Kirch, W., et al.: High prevalence and poor control of hypertension in primary care: cross-sectional study. J. Hypertens. 22 (2004), 479-486.
23. Thamm, M.: Blutdruck in Deutschland-aktueller Status und Trends. Gesundheitswesen 61 Spec. No (1999), S90-93.
24. Wittchen, H. U., Glaesmer, H., Marz, W., et al.: Cardiovascular risk factors in primary care: methods and baseline prevalence rates-the DETECT program. Curr. Med. Res. Opin. 21 (2005), 619-630.
25. Wolf-Maier, K., Cooper, R. S., Kramer, H., et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004), 10-17.